Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
GSK has reached an up to $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns hanging over the UK drugmaker.
The company said on Wednesday it had reached agreements with 10 plaintiff firms representing about 80,000 people who had brought product liability cases against it in US…
Read the full article here